Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€316.90
29.11.21
-
29.11.22
-49.87%
30.11.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€321.00
28.11.21
€400.00
28.11.22
-25.79%
12.12.21

Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
Standard Investments for future growth
Capable Management
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€321.00
27.11.21
-
27.11.22
-53.21%
28.11.22

buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€260.50
21.11.21
€304.00
21.11.22
-37.83%
30.03.22

Could be worthwhile Investment >10% per year
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€222.70
16.11.21
€250.00
16.11.22
-18.12%
13.01.22

Significant cyclical dependencies
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€212.70
15.11.21
€170.00
15.11.22
-35.14%
28.04.22

Good rating
Medium risks for its business
Very low/no dividend yield expected
high free float
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€211.50
15.11.21
€250.00
15.11.22
51.77%
27.11.21

buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€210.00
14.11.21
€185.00
14.11.22
-25.98%
15.11.22

EBIT growth > 30% per year expected
Higher EBIT margin than peer group
Fair valuation
Higher risks for its business
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€210.00
13.11.21
-
13.11.22
-21.33%
14.07.22

buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€204.60
09.11.21
€260.00
09.11.22
-27.30%
30.01.22

Innovative
Some uniques
overvalued
Below average Management
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€213.90
09.11.21
-
09.11.22
-26.02%
10.11.22

buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€196.95
08.11.21
-
08.11.22
6.63%
13.11.21

Could be worthwhile Investment >10% per year
Top 10 in its market
Future proof or reliable business model
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€187.10
05.11.21
-
05.11.22
12.24%
14.11.21

BioNTech SE ADR

Start price
Target price
Perf. (%)
€212.30
18.10.21
-
18.10.25
-29.82%
23.08.22

Probably not worthwhile Investment
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€214.30
16.10.21
-
16.10.22
-27.30%
29.03.22

BioNTech SE ADR

Start price
Target price
Perf. (%)
€214.00
13.10.21
€120.00
13.10.24
-39.58%
14.06.22

BioNTech SE ADR

Start price
Target price
Perf. (%)
€214.50
13.10.21
€170.00
13.10.24
-38.48%
15.06.22

BioNTech SE ADR

Start price
Target price
Perf. (%)
€211.40
13.10.21
€130.00
13.10.24
-60.36%
16:33

Revenue decline/stagnation expected
Increased challenges to pay loans and raise capital
Risky balance sheet
Low dividend yield expected
BioNTech SE ADR

Start price
Target price
Perf. (%)
€212.20
13.10.21
€100.00
13.10.22
-39.07%
14.06.22

BioNTech SE ADR

Start price
Target price
Perf. (%)
€212.40
13.10.21
€150.00
13.10.22
-37.88%
15.06.22

buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€216.70
05.10.21
€265.00
05.10.22
-37.06%
28.09.22

Could be worthwhile Investment >10% per year
Strong uniques
Market Leader or Top 3
Dependend from some customers or products
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€209.40
04.10.21
-
04.10.22
2.34%
18.10.21

buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€291.70
23.09.21
-
23.09.25
-67.72%
12.01.24

Innovative
Market Leader or Top 3
Revenue growth > 30% per year expected
High risks in the balance sheet
buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€277.00
13.09.21
-
13.09.22
-21.59%
14.10.21

buy
BioNTech SE ADR

Start price
Target price
Perf. (%)
€289.50
08.09.21
€333.00
08.09.22
-49.48%
09.09.22

Could be worthwhile Investment >10% per year
Capable Management
Growths faster than the competition
Higher risks for its business